Eli Lilly and Company
LLY
$1179.11
+0.85%
Eli Lilly is a global pharmaceutical company focused on neuroscience, cardiometabolic, cancer, and immunology, with key products including Mounjaro, Zepbound, Verzenio, and Taltz. As a market leader in the rapidly expanding GLP-1 receptor agonist class for diabetes and obesity, Lilly's competitive edge lies in its first-mover advantage and robust pipeline. The current investor narrative centers on the accelerating growth of its weight-loss drug franchise, which now accounts for nearly two-thirds of revenue, and recent regulatory wins including Medicare coverage expansion for obesity medications, driving the stock to new all-time highs. Debate persists around concentration risk, competitive threats from Novo Nordisk and Viking Therapeutics, and the sustainability of margin expansion as the company scales production.…
LLY
Eli Lilly and Company
$1179.11
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating: Buy. Eli Lilly is a high-growth pharmaceutical leader with accelerating revenue, expanding margins, and a dominant position in the GLP-1 market. The consensus analyst rating is Buy with an average target of $1,270, implying 9.8% upside. Supporting evidence: (1) Revenue growth accelerated to 55.6% YoY, the highest in recent quarters; (2) Net margin improved to 37.4% from 21.7% a year ago; (3) Forward P/E of 25.8x is reasonable given expected EPS growth, with a PEG ratio of 0.49 suggesting undervaluation relative to growth; (4) Free cash flow of $13.58B TTM provides financial flexibility. Risks that could invalidate the thesis: (1) Competitive erosion from Viking or Novo Nordisk; (2) Regulatory setbacks for label expansions; (3) Multiple compression if growth decelerates. This Buy would downgrade to Hold if revenue growth falls below 30% or if competitive data shows clear superiority. The stock appears fairly valued to slightly undervalued given its growth trajectory, with the forward P/E of 25.8x below the historical average for high-growth pharma.
Sign up to view all
LLY 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Lilly's accelerating revenue growth and expanding margins provide a strong fundamental foundation, while the forward P/E of 25.8x and PEG of 0.49 suggest the stock is undervalued relative to its growth rate. Analyst sentiment is firmly positive, and the low beta offers a favorable risk/reward. However, the medium confidence reflects the binary risk from competitive dynamics in the GLP-1 market. An upgrade to high confidence would require clear evidence of sustained market leadership, while a downgrade to neutral would follow signs of competitive erosion or margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1270.37 and implied upside of +7.7% versus the current price.
Average Target
$1270.37
0 analysts
Implied Upside
+7.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$850 - $1600
Analyst target range
The stock is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.76 on a 1-5 scale). The average target price is $1,270.37, implying approximately 9.8% upside from the current price of $1,156.63. The distribution leans heavily bullish, with recent ratings from Citigroup, UBS, Guggenheim, BofA, Truist, Morgan Stanley, RBC, and JP Morgan all maintaining Buy or Overweight ratings. The target range spans from a low of $850.00 to a high of $1,600.00. The high target of $1,600 assumes continued strong growth from the GLP-1 franchise, potential label expansions, and multiple expansion. The low target of $850 reflects risks such as competitive pressure from Novo Nordisk and Viking Therapeutics, pricing headwinds, or pipeline setbacks. The wide spread ($750) indicates high uncertainty, but the consensus remains firmly bullish. Recent analyst actions show no downgrades, with all 10 listed firms reiterating positive ratings, reinforcing strong institutional conviction. The lack of negative revisions suggests confidence in Lilly's near-term outlook, though the wide target range reminds investors of the binary risks inherent in pharmaceutical stocks.
Drowning in data?
Find the real signal!
Bulls vs Bears: LLY Investment Factors
Eli Lilly presents a compelling growth story driven by its dominant GLP-1 franchise, with accelerating revenue growth of 55.6% and expanding margins. The bull case is supported by strong analyst conviction, low beta, and robust cash flow. However, extreme revenue concentration, premium valuation, and competitive threats from Viking and Novo Nordisk introduce significant risks. The single most important tension is whether Lilly can maintain its GLP-1 market leadership against emerging competition; if it does, the stock could re-rate higher, but if it loses share, multiple compression could be severe. Currently, the bull case has stronger evidence given the accelerating growth trajectory and regulatory tailwinds, but investors must monitor competitive developments closely.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 55.6% YoY to $19.8B, accelerating from 51.5% in Q4 2025 and 36.6% in Q3 2025, driven by the GLP-1 franchise which now accounts for 79.6% of total revenue.
- Expanding Profit Margins: Net margin improved to 37.4% in Q1 2026 from 21.7% a year ago, while operating margin expanded to 44.7% from 42.8%, reflecting strong operating leverage as revenue scales.
- Strong Analyst Conviction: 27 analysts rate the stock a Buy with a mean rating of 1.76, and the average target price of $1,270 implies 9.8% upside. No recent downgrades have been issued.
- Low Volatility with High Growth: With a beta of 0.51, Lilly offers downside protection while delivering 49.9% annual returns, significantly outperforming the S&P 500's 20.9% gain.
Bearish
- Extreme Revenue Concentration: The cardiometabolic segment (Mounjaro/Zepbound) generates 79.6% of total revenue, creating significant risk if competition erodes market share or pricing.
- Premium Valuation Multiple: Trailing P/E of 46.7x and EV/EBITDA of 35.8x are elevated, leaving the stock vulnerable to multiple compression if growth decelerates or sentiment shifts.
- Competitive Threat Intensifying: Viking Therapeutics' VK2735 shows superior efficacy and dual-formulation potential, while Novo Nordisk's $149 Wegovy pill could disrupt pricing dynamics.
- High Debt-to-Equity Ratio: Debt-to-equity of 1.60 indicates significant leverage, which could strain the balance sheet if cash flows decline or interest rates remain elevated.
LLY Technical Analysis
Eli Lilly is in a sustained uptrend, with the stock up 49.9% over the past year, significantly outperforming the S&P 500's 20.9% gain. The current price of $1,156.63 sits at 92.6% of its 52-week range ($623.78–$1,249.45), indicating strong momentum near the highs, though not yet overextended. This positioning suggests bullish sentiment but warrants caution as the stock approaches resistance. Short-term momentum is accelerating, with a 1-month gain of 2.4% and a 3-month gain of 27.9%, the latter outpacing the 1-year trend. The 3-month relative strength of 21.7% versus the S&P 500 confirms strong near-term outperformance. However, the 1-month relative strength of 1.8% suggests a slight deceleration, which could signal a temporary pullback or consolidation before the next leg higher. The 52-week high of $1,249.45 serves as key resistance; a breakout above this level would signal a continuation of the uptrend. Support lies near the 52-week low of $623.78, though more immediate support is around the $1,100 area. With a beta of 0.51, Lilly is significantly less volatile than the market, meaning it offers downside protection but may lag during sharp market rallies. This low beta is attractive for risk-averse investors seeking exposure to high-growth pharma.
Beta
0.51
0.51x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$624-$1249
Price range past year
Annual Return
+54.8%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | +0.3% |
| 3m | +27.2% | +4.7% |
| 6m | +13.6% | +7.5% |
| 1y | +54.8% | +18.4% |
| ytd | +9.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is accelerating sharply, with Q1 2026 revenue of $19.8 billion representing a 55.6% year-over-year increase, up from 51.5% growth in Q4 2025 and 36.6% in Q3 2025. The cardiometabolic segment (including Mounjaro and Zepbound) generated $15.76 billion in the latest quarter, accounting for 79.6% of total revenue and driving the acceleration. Oncology contributed $2.27 billion, while immunology and neuroscience added $1.20 billion and $0.38 billion, respectively. This growth trajectory underscores the blockbuster potential of Lilly's GLP-1 franchise and supports a bullish investment case. Profitability is robust and improving, with Q1 2026 net income of $7.40 billion and a net margin of 37.4%, up from 34.4% in Q4 2025 and 21.7% in Q1 2025. Gross margin remains high at 81.9%, while operating margin expanded to 44.7% from 42.8% a year ago, reflecting operating leverage as revenue scales. The company is solidly profitable with an EPS of $8.27, and margins are trending upward, which is typical for high-growth pharma with patent-protected products. The balance sheet is healthy but leveraged: debt-to-equity stands at 1.60, and the current ratio is 1.58, indicating adequate liquidity. Free cash flow (TTM) is $13.58 billion, providing ample capacity for internal investment and shareholder returns. ROE is exceptional at 77.8%, reflecting high profitability relative to equity. The company generated $5.33 billion in operating cash flow in Q1 2026, covering capital expenditures of $2.33 billion and dividends of $1.55 billion, with $3.01 billion in free cash flow. This strong cash generation reduces reliance on external financing and supports a low financial risk profile.
Quarterly Revenue
$19.8B
2026-03
Revenue YoY Growth
+55.5%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given net income is positive ($7.40 billion), the trailing P/E ratio of 46.7x is the primary valuation metric. The forward P/E of 25.8x implies a significant earnings growth expectation, with the gap between trailing and forward multiples reflecting the market's anticipation of continued strong EPS expansion. The PEG ratio of 0.49 suggests the stock is undervalued relative to its growth rate, though this depends on the accuracy of growth estimates. Compared to the industry average P/E (not provided), Lilly's trailing P/E of 46.7x appears elevated, but the forward P/E of 25.8x is more reasonable. The EV/EBITDA of 35.8x and EV/Sales of 14.8x also indicate a premium valuation, likely justified by the company's superior growth and profitability. Historically, Lilly's trailing P/E has ranged from roughly 28x to 205x over the past three years. The current 46.7x is below the mid-range, suggesting the stock is not at extreme valuation levels. The price-to-book ratio of 36.4x is near the high end of its historical range (26x–61x), reflecting the market's premium on its intangible assets and future growth. Overall, the valuation appears reasonable given the growth trajectory, but investors should monitor for any signs of deceleration that could compress multiples.
PE
46.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Lilly's debt-to-equity of 1.60 and interest expense of $332M in Q1 2026 indicate meaningful leverage, though operating cash flow of $5.33B covers interest 16x over. The extreme concentration in GLP-1 drugs (79.6% of revenue) creates dependency on a single product class; any setback in manufacturing, pricing, or efficacy could severely impact earnings. Net margin expansion to 37.4% is impressive but may be unsustainable if competitive pricing pressures emerge. Market & Competitive Risks: The stock's trailing P/E of 46.7x is well above the broader market, making it susceptible to valuation compression if growth decelerates. Competitors like Viking Therapeutics (VK2735 with superior efficacy data) and Novo Nordisk (aggressive $149 Wegovy pill pricing) pose direct threats. Recent news highlights Novo's volume-over-pricing strategy, which could erode Lilly's pricing power. With a beta of 0.51, the stock is less correlated to macro moves but still exposed to sector rotation out of growth. Worst-Case Scenario: A scenario where Viking's oral GLP-1 drug gains FDA approval with superior efficacy, Novo's pricing war compresses margins, and Lilly's pipeline disappoints could drive the stock to the analyst low target of $850, representing a 26.5% decline from the current price of $1,156.63. This aligns with the 52-week low of $623.78, implying a potential 46.1% loss in an extreme adverse scenario.
FAQ
The key risks are: (1) Competitive risk: Viking Therapeutics' VK2735 and Novo Nordisk's $149 Wegovy pill could erode market share and pricing power; (2) Concentration risk: 79.6% of revenue comes from cardiometabolic drugs, making the company vulnerable to any setback in that segment; (3) Valuation risk: The trailing P/E of 46.7x leaves little room for error; if growth decelerates, multiple compression could be severe; (4) Regulatory risk: Delays or failures in label expansions or new drug approvals could disappoint growth expectations. The most severe risk is competitive disruption, which could drive the stock to the analyst low target of $850, a 26.5% decline.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading near the analyst average target of $1,270, implying 9.8% upside, driven by continued GLP-1 growth and stable margins. The bull case (30% probability) targets $1,300-$1,600, driven by label expansions and oral GLP-1 success. The bear case (20% probability) sees the stock falling to $850-$1,000 if competitive pressures intensify. The most likely scenario is the base case, assuming Lilly maintains its market leadership without major disruptions. Key assumptions include revenue growth moderating to 30-40% and net margins stabilizing around 35%.
LLY appears fairly valued to slightly undervalued based on its growth prospects. The trailing P/E of 46.7x is elevated, but the forward P/E of 25.8x reflects the market's expectation of strong EPS growth. The PEG ratio of 0.49 indicates the stock is undervalued relative to its growth rate, which is rare for a large-cap pharma. Compared to its historical P/E range of 28x-205x, the current 46.7x is below the midpoint. The EV/EBITDA of 35.8x and EV/Sales of 14.8x are premium but justified by the company's superior growth and profitability. The market is pricing in continued success of the GLP-1 franchise, but not yet fully discounting potential label expansions and pipeline wins.
LLY is a good buy for growth-oriented investors with a moderate risk tolerance. The stock offers a compelling risk/reward with 9.8% upside to the average analyst target of $1,270 and a forward P/E of 25.8x, which is reasonable given expected EPS growth. The PEG ratio of 0.49 suggests the stock is undervalued relative to its growth rate. However, the biggest downside risk is competitive pressure from Viking and Novo, which could compress margins and multiples. For long-term investors who believe in the GLP-1 franchise's durability, LLY is a strong buy; for short-term traders, the wide target range ($850-$1,600) implies high uncertainty.
LLY is more suitable for long-term investment due to its growth stage, low beta of 0.51, and strong earnings visibility from patent-protected products. The company's accelerating revenue growth (55.6% YoY) and expanding margins support a multi-year growth thesis. The dividend yield of 0.56% is modest but growing, with a payout ratio of 26.1%. Short-term trading is possible given the stock's momentum, but the wide analyst target range ($850-$1,600) introduces significant volatility risk. A minimum holding period of 3-5 years is recommended to capture the full value of the GLP-1 franchise and pipeline. For long-term investors, the low beta provides downside protection, making it a core holding in a growth portfolio.
